NCT05349357

Brief Summary

Neurodynamics, i.e., the mobilization of the peripheral nervous system, is a physical approach to the treatment of pain; the method relies on influencing pain physiology via mechanical treatment of neural tissues and the non-neural structures surrounding the nervous system. Neural mobilization (NM) is used to treat various disorders of the nervous system concerning the length and mobility of peripheral nerves, as the nerve mobilizing refers to techniques that help to reestablish motion between a nerve and its surrounding soft tissues, thus to treat the nerves that have become entangled within the soft tissue, as it leads to tension release on a nerve by stretching and pulling one end of the nerve during keeping the other end in a relaxed state.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 15, 2022

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 27, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

June 25, 2022

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2023

Completed
Last Updated

March 9, 2023

Status Verified

March 1, 2023

Enrollment Period

8 months

First QC Date

April 15, 2022

Last Update Submit

March 7, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Michigan neuropathy screening instrument

    For screening the neuropathy; The MNSI questionnaire is self-administered. Responses are added to obtain a total score. 'Yes' responses to questions 1-3, 5-6, 8-9, 11-12, 14-15 are each counted as one point. 'No' responses to questions 7 and 13 each count as one point. Question 4 was considered to be a measure of impaired circulation and question 10 a measure of general asthenia and were not included in the published scoring algorithm. A score of ≥ 7 was considered abnormal. All 15 questions were included in the new scoring algorithms.

    3 weeks

  • Numerical Pain Rating Scale

    Quantify the pain ranging from 0 to 10 in which zero means no pain and 10 severe pain

    3 weeks

Secondary Outcomes (1)

  • Quality of Life SF-36

    3 weeks

Study Arms (2)

Group A

ACTIVE COMPARATOR

TENS, Stretching exercises, ROM exercises Sliding neural mobilization to femoral, sciatic, tibial nerve

Other: Sliding Neural mobilizationOther: Stretching exercisesDevice: TENS

Group B

ACTIVE COMPARATOR

TENS, Stretching exercises, ROM exercises Tensioner neural mobilization to femoral, sciatic, tibial nerve

Other: Tensioner Neural mobilizationOther: Stretching exercisesDevice: TENS

Interventions

Sliding neural mobilization to femoral, sciatic and tibial nerve

Group A

Tensioner neural mobilization to femoral, sciatic and tibial nerve

Group B

Stretching exercises

Group AGroup B
TENSDEVICE

TENS

Group AGroup B

Eligibility Criteria

Age50 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient having≥12score on Self report Leads Assessment of Neuropathic Symptoms and Sign
  • Patients with lower limb pain ≥4 to ≤7 on NPRS

You may not qualify if:

  • Diabetic foot ulcer
  • Complex regional pain syndrome
  • Infection in lower limb
  • Lower extremity amputation
  • Discogenic pain
  • Restricted joint deformity
  • Dependency on chemical or drugs
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

DHQ Hospital

Mianwali, Punjab Province, Pakistan

Location

Related Publications (4)

  • Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042. No abstract available.

    PMID: 27999003BACKGROUND
  • Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, Lim J, Malik RA, Alam U. Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clin Ther. 2018 Jun;40(6):828-849. doi: 10.1016/j.clinthera.2018.04.001. Epub 2018 Apr 30.

    PMID: 29709457BACKGROUND
  • Feldman EL, Nave KA, Jensen TS, Bennett DLH. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron. 2017 Mar 22;93(6):1296-1313. doi: 10.1016/j.neuron.2017.02.005.

    PMID: 28334605BACKGROUND
  • Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. Epub 2018 Feb 26.

    PMID: 29496507BACKGROUND

MeSH Terms

Interventions

Muscle Stretching ExercisesTranscutaneous Electric Nerve Stimulation

Intervention Hierarchy (Ancestors)

Exercise TherapyRehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy ModalitiesExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological PhenomenaElectric Stimulation TherapyAnalgesiaAnesthesia and Analgesia

Study Officials

  • Mirza Obaid Baig, MSPT(NMR)

    Riphah International University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 15, 2022

First Posted

April 27, 2022

Study Start

June 25, 2022

Primary Completion

February 28, 2023

Study Completion

February 28, 2023

Last Updated

March 9, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations